Guy-Charles Fanneau de La Horie, CEO
Dr Fanneau de La Horie has over 20 years of experience in the pharmaceutical and biotechnology industries. Before joining Pherecydes Pharma, he held a number of international management roles, including posts at Schering-Plough, Biogen and IDM, in both Europe and the US.
More recently, he was managing director of PathoQuest, a company developing a NGS-based infectious disease diagnostic technology. Between 2006 and 2013 he was the CEO of Neovacs and coordinated the 2010 IPO.
Prior to that, he spent eight years with Biogen, where he set up and ran the subsidiaries in France and Benelux. During his time with Biogen he managed the $700M salesforce in the US and held Europe-wide responsibilities for marketing, regulatory and medical affairs. A graduate of the National Veterinary School in Lyon, France (1982), Dr Fanneau de La Horie also holds an MBA from INSEAD, awarded in 1988.
Jérôme Gabard, COO
Starting at the bench in DuPont de Nemours plant biotechnology research facility (Wilmington, DE, USA) in the late eighties, Jérôme has been since developing professional skills in marketing and business development.
Prior to join Pherecydes Pharma he was Life Sciences Director at The Marketech Group, to develop company sales and to perform strategic and operational market research studies for start up’s or big pharma.
He is experienced in managing private innovative R&D start up’s (Euroclide) and to build value through merger-acquisition (Faust Pharmaceuticals, today Domain Therapeutics).
During his career he has been involved in a variety of R&D industrial projects, related to plant biotechnology, crop protection, food pathogen diagnostics, information management and drug discovery.
Magali Vidal-Engaurran, Senior Pharmacist and Qualified Person
The professional career of Magali Vidal-Engaurran started with manufacturing assignments before turning to Quality Assurance. During these experiences, she acquired sterile products and biotechnology skills in pharmaceutical laboratories such as Guerbet and Stallergenes Greer.
Most recently, Magali was Interim Lead Pharmacist and Head of Operational Quality Assurance for the Stallergenes Greer site and, as such, gained various experiences such as starting-up a new production site and obtaining FDA approval.
During her career, Magali has been involved in continuous improvement projects, has managed changes in the production method and layout of premises in line with the evolution of regulations and has participated in the redaction of numerous regulatory files.
The Medical Director takes care of all the medical aspects related to the treatments and clinical studies of Pherecydes Pharma.
She is also involved in the regulatory aspects of phage therapy.
Patrick Champion-Arnaud, CMO
Patrick is an expert in biologicals manufacturing. Before joining Pherecydes, he was Scouting Manager at Valneva in Nantes, a Biotechnology Co. involved in vaccine development. Patrick has been working on flu, pox, herpes, lenti, adeno… viruses to name a few.
His knowledge in virology coupled to vaccine manufacturing process development is a good combination to develop pharmaceutical bacteriophage drugs.
Patrick worked also at the Harvard Medical School (Boston, MA, USA) after getting his PhD in molecular virology from Nantes University (France).
Cindy Fevre, CSO
Cindy is a microbiologist, expert in bacteriology. She got her PhD from Pierre & Marie Curie University at the Pasteur Institute (Paris, France). She studied antibiotic resistance, virulence and genetic diversity of Klebsiella genus. Afterwards, she worked on other major clinical pathogens such as Listeria and Staphylococcus aureus.
Before joining Phercydes Pharma, Cindy also developped a new Phage Display method and acquired a deep knowledge in bacteriophage biology and genomics.
Through an international experience (UMC Utrecht, Netherlands) she managed research collaboration with industrial potential and led a team of pluridisciplinar and multicultural researchers.
Laure Saujet, R&D projects coordinator
Laure replaced Cindy Fevre, CSO, during her maternity leave at Pherecydes Pharma, from December 2017 to September 2018. She is currently a R&D projects coordinator.
She has a PhD on microbiology obtained in 2013 at the Pasteur Institute. After her thesis, she worked on hydrogenases at the CEA of Saclay for one year. Then, she worked as a synthetic biology project manager.
As first employee of this start up, she was responsible of the development of genetically modified bacteriophages specifically targeting adherent invasive E. coli implicated in Crohn's disease.
She published 12 scientific articles including 3 in first author.
Gaëlle Demarre, Senior Scientist
Gaëlle become a member of the Pherecydes Pharma team in May 2018.
She obtained a PhD at the Pasteur Institute (Paris) studying the natural vectors of antibiotic resistance, responsible for their dissemination.
During 4 years, she put forward her skills at the National Institutes of Health (USA, Bethesda), on Vibrio cholerae.
After roaming, she joined the CNRS, then the Collège de France (Paris, France) where she studied an invasive and adherent strain of Escherichia coli associated with the Crohn disease.
Gaëlle brought up a major public health problem: Bacteria sensitive to antibiotics may become persistant in presence of antibiotics and so survive to those antibiotic treatments.
Pherecydes brings together a multidisciplinary team of PhD, veterinarian, engineers, assistant engineers and technicians.